Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1071-1077

  Wagener, Matthew ^a   Zhang, Xiaochun ^a   Villarreal, Humberto G ^a   Levy, Larry ^a   Allen, Pamela ^a   Shentu, Shujun ^a   Fang, Bingliang ^a   Krishnan, Sunil ^a   Chang, Joe Y ^a   Cheung, M Rex ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti epidermal growth factor receptor antibody; DU145; Epidermal growth factor receptor; Prostate cancer; Radiation sensitivity

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOCORTIN 5; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG SCREENING; FLOW CYTOMETRY; GAMMA IRRADIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTHERAPY; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 47549089067     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1071     Document Type: Article

References (49)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Oesterling JE, Fuks Z, Lee CT and Scher HI: Cancer of the Prostate. In: Cancer Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds). Vol 1, Lippincott-Raven, Philadelphia, pp1322-1385, 1997.
3. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998.
4. Pollack A, Zagars GK, Starkschall G, et al: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097-1105, 2002.
5. Zelefsky MJ, Fuks Z, Hunt M, et al: High-dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53: 1111-1116, 2002.
6. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103-106, 2002.
7. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M and Dobs AS: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 56: 779-786, 2002.
8. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A and Kantoff PW: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821-827, 2004.
9. Padula GD, Zelefsky MJ, Venkatraman ES, Fuks Z, Lee HJ, Natale L and Leibel SA: Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52: 439-443, 2002.
10. Baumann M and Krause M: Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72: 257-266, 2004.
11. Harari PM and Huang SM: Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 58: 976-983, 2004.
12. Scudiero DA, Shoemaker RH, Paull KD, et al: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4833, 1988.
13. Milas L, Fan Z, Andratschke NH and Ang KK: Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58: 966-971, 2004.
14. Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154, 1989.
15. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B and Reutelingsperger CP: Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31: 1-9, 1998.
16. Verbeke G and Molenberohs G: Linear Mixed Models for Longitudinal Data. Springer-Verlag, New York, NY, 2000.
17. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
18. Carpenter G and Cohen S: Epidermal growth factor. Annu Rev Biochem 48: 193-216, 1979.
19. Ogiso H, Ishitani R, Nureki O, et al: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787, 2002.
20. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
21. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000.
22. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nad Acad Sci USA 101: 13306-13311, 2004.
23. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
24. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
25. Scher HI, Sarkis A, Reuter V, et al: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1: 545-550, 1995.
26. Zellweger T, Ninck C, Bloch M, et al: Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113: 619-628, 2005.
27. Di Lorenzo G, Tortora G, D'Armiento FP, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002.
28. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E and Hynes NE: ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 56: 142-149, 2003.
29. Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ and Shu HK: Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23: 4594-4602, 2004.
30. Lammering G, Hewit TH, Holmes M, et al: Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radio sensitivity. Clin Cancer Res 10: 6732-6743, 2004.
31. Ang KK, Andratschke NH and Milas L: Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58: 959-965, 2004.
32. Sgambato A, Faraglia B, Ardito R, et al: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 201: 97-105, 2004.
33. Bonner JA, Buchsbaum DJ, Rogers BE, et al: Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. Int J Radiat Oncol Biol Phys 58: 950-958, 2004.
34. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D and Halpern AC: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144: 1169-1176, 2001.
35. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
36. Rewcastle GW, Palmer BD, Thompson AM, et al: Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]-pyrido [d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J Med Chem 39: 1823-1835, 1996.
37. Mimeault M, Pommery N and Henichart JP: Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines. Int J Cancer 106: 116-124, 2003.
38. Barker AJ, Gibson KH, Grundy W, et al: Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-1914, 2001.
39. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ and Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
40. Barnes DW: Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol 93: 1-4, 1982.
41. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH and Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341, 1983.
42. Gill GN and Lazar CS: Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 293: 305-307, 1981.
43. King AC and Cuatrecasas P: Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem 257: 3053-3060, 1982.
44. Zhang L, Gjoerup O and Roberts TM: The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci USA 101: 10296-10301, 2004.
45. Klein P, Mattoon D, Lemmon MA and Schlessinger J: A structure-based model for ligand binding and dimerization of EGF receptors. Proc Natt Acad Sci USA 101: 929-934, 2004.
46. Sgambato A, Camerini A, Faraglia B, et al: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. Cell Physiol 201: 97-105, 2004.
47. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P and Hagan MP: Epidermal growth factor and ionizing radiation upregulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159: 439-452, 2003.
48. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C and Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780-2785, 1991.
49. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H and Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56: 3666-3669, 1996.